Daniel D. Long sold $533k of SEPN
SVP, Drug Discovery at Septerna, Inc.. 15,000 shares at an average of $35.51, traded Jun 22, 2026, filed Jun 24, 2026.
Score components
- +15RoleOfficer
- +18Trade size$533k at market
- +5Share of holdings soldSold 13% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-281461, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | MOption exercise Common Stock10b5-1 | +10,529 | $2.76 | $29k | 106,941 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Common Stock10b5-1 | +4,471 | $11.70 | $52k | 111,412 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stock10b5-1 | -8,000 | $35.10 | $281k | 103,412 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stock10b5-1 | -7,000 | $35.97 | $252k | 96,412 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -10,529 | $0.00 | $0 | 10,376 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,471 | $0.00 | $0 | 25,529 | Jun 24, 2026 |
Related signals
Other insiders at Septerna, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Septerna, Inc. | Daniel D. Long SVP, Drug Discovery | $126k 3,333 shares | -3% | |
| 65Notable | Septerna, Inc. | Ra Capital Management, L.p. director, owner | $63M 1,493,000 shares | -27% | |
| 32Weak | Septerna, Inc. | Third Rock Ventures V, L.P. owner | $7.4M 147,200 shares | -2% | |
| 30Weak | Septerna, Inc. | Elizabeth Bhatt President and COO | $1.1M 25,000 shares | -13% | |
| 5Weak | Septerna, Inc. | Daniel D. Long SVP, Drug Discovery | $115k 3,334 shares | -3% | |
| 4Weak | Septerna, Inc. | Elizabeth Bhatt President and COO | $136k 4,000 shares | -2% | |
| 5Weak | Septerna, Inc. | Daniel D. Long SVP, Drug Discovery | $115k 3,333 shares | -3% | |
| 16Weak | Septerna, Inc. | Samira Shaikhly Chief People Officer | $77k 2,178 shares | -73% | |
| 20Weak | Septerna, Inc. | Samira Shaikhly Chief People Officer | $219k 6,250 shares | -89% | |
| 11Weak | Septerna, Inc. | Samira Shaikhly Chief People Officer | $172k 5,935 shares | -88% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.